HDAC9 and malaria: HDAC inhibitors are also being studied for inhibition of human parasitic infections, including malaria, toxoplasmosis, trypanosomiasis, schistosomiasis and leishamaniasis (Andrews et al., 2009, Andrews et al., 2012).